If you have the PI3K upregulation then GDC for sure of the two but VAL has the advantage of being across the board so may be more useful to that subgroup.
I suspect though if CHM's CAR T has anything like the results they have in other cancers that will take a big chunk of the market.
Delays are going to be costly in this space in the DCF models of bio analysts.
